Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with leftventricular hypertrophy: Sub-analysis of the KYOTO HEART study.
These left-ventricular leads are intended to improve the efficiency of the heart in patients with heart failure, but are not responsible for delivering immediate life-sustaining pacing or life-saving defibrillation therapy.